Drug and Therapeutics Bulletin 1995;33:47-48; doi:10.1136/dtb.1995.33647
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder

Relevant BNF section: 4.3.3

Since we reviewed the selective serotonin reuptake inhibitor (SSRI) antidepressants two years ago1 two of them, fluoxetine (Prozac - Dista) and fluvoxamine (Faverin - Duphar), have also been licensed for the treatment of patients with obsessive-compulsive disorder. How do these and the other SSRIs available in the UK - paroxetine (Seroxat - SmithKline Beecham) and sertraline (Lustral - Invicta/Pfizer) - compare with clomipramine, a standard drug treatment for this disorder?2,3






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.